646-ph
VANCOUVER, BC , Dec. 9, 2024 /PRNewswire/ - Seaspan Corporation (Seaspan), world leading independent containership lessor, has signed an agreement to equip its fleet with the OneWeb advanced low-earth orbit (LEO) satellite offering from KVH Industries. This marks the next step in Seaspan's drive to deliver shore-like internet connectivity at sea, supporting its digital transformation strategy and augmenting its fleet's existing LEO services. As an early adopter of LEO technologies, Seaspan is the first major owner/operator of containerships to partner with KVH for its OneWeb solution. Seaspan's OneWeb rollout will further strengthen the fleet's data connectivity infrastructure, enabling Seaspan to leverage advanced technologies and high bandwidth-demanding applications, including solutions such as cloud-based software as a service (SaaS) technology that were previously unsuitable for maritime use. "Our partnership with KVH for OneWeb services aligns with our strategy of providing a best-in-class communication experience across our fleet," said Garret Wong , Seaspan's Vice President of Information Technology. "This initiative brings us closer to realizing shore-like connectivity at sea while enhancing efficiency, safety, and seafarer welfare." Adrian Alb, Senior Manager of IT Operations at Seaspan, added "LEO satellite technologies have set a new benchmark for vessel communications, offering high-bandwidth, low latency, and reliability far beyond traditional marine satellite solutions. This collaboration with KVH aligns with our goal of enhancing provider diversity and minimizing geographical blackout zones, further bolstering the robustness of our satellite communications infrastructure." Chad Impey , Senior Vice President for Global Sales at KVH, commented, "We are proud to support Seaspan with the planned deployment of OneWeb service and hardware as part of our integrated KVH ONE multi-orbit, multi-channel network solution." With the integration of OneWeb LEO technology from KVH Industries, Seaspan continues to demonstrate its commitment to adopting cutting edge technologies enabling its fleet to meet the demands of modern maritime operations. About Seaspan Corporation Seaspan is the world's leading maritime asset-owner and operator focussed on long-term, fixed-rate leases to the world's most prominent shipping lines. As of September 30, 2024 , Seaspan's operating fleet consisted of 218 vessels, pro forma for undelivered newbuilds including PCTCs, with a total fleet capacity of approximately 2.3 million TEU on a fully delivered basis. For more information, visit seaspancorp.com . About KVH Industries, Inc. KVH Industries, Inc. is a global leader in maritime and mobile connectivity delivered via the KVH ONE® network. The company, founded in 1982, is based in Middletown, RI , with research, development, and manufacturing operations in Middletown, RI , and more than a dozen offices around the globe. KVH provides connectivity solutions for commercial maritime, leisure marine, military/government, and land mobile applications on vessels and vehicles, including the TracNetTM, TracPhone®, and TracVision product lines, the KVH ONE OpenNet Program for non-KVH antennas, AgilePlans® Connectivity as a Service (CaaS), and the KVH Link crew wellbeing content service. KVH Industries, Inc., has used, registered, or applied to register its trademarks in the USA and other countries around the world, including but not limited to the following marks: KVH, KVH ONE, TracVision, TracPhone, TracNet, and AgilePlans. Other trademarks are the property of their respective companies. View original content to download multimedia: https://www.prnewswire.com/news-releases/seaspan-corporation-signs-agreement-with-kvh-to-equip-fleet-with-oneweb-low-earth-orbit-solution-302326768.html SOURCE Seaspan Corporation
Key Leadership Appointments Bring New Skills and Capabilities to Organization EMERYVILLE, Calif. , Dec. 13, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced the recent appointments of Dan Maziasz as Chief Business Officer, Cara Bauer as Chief Human Resources Officer, and Tracy Rossin as Senior Vice President of Corporate Affairs, Communications and Investor Relations. "I'm pleased to welcome three industry leaders to our Kyverna team," said Warner Biddle , Chief Executive Officer of Kyverna. "Dan, Cara and Tracy bring important new skills and capabilities to Kyverna as we continue to support the company's next phase of growth and work to bring a transformative change to patients living with severe autoimmune diseases." Mr. Maziasz brings over 25 years of leadership and business experience across several leading biotechnology and large pharmaceutical companies. Mr. Maziasz most recently served as Chief Business Officer at Atara Biotherapeutics, the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. At Atara, Mr. Maziasz led various corporate initiatives including strategic planning, licensing transactions with industry partners, and research collaborations with academic groups. Before his time at Atara, Mr. Maziasz was Vice President, Corporate Strategy and Business Development at Kite Pharma, a global cell therapy leader, prior to its acquisition by Gilead Sciences. Mr. Maziasz also spent more than a decade at Amgen, where he held roles of increasing responsibility in the US, Europe , and Asia across business development, corporate strategy, finance, and commercial functions. Ms. Bauer brings more than 25 years of experience in global human resources leadership to Kyverna, having served most recently as Global Head of Human Resources at Kite, a Gilead Company, where she oversaw all HR strategy and operations during a period of hypergrowth and global expansion which strengthened the company's leadership position in cell therapy. Prior to this role, she served as the Global Head of HR for the Entertainment Division at Riot Games where she worked directly with the founders to build an Entertainment Studio separate from the core gaming business. Ms. Bauer has also held various HR leadership roles at companies such as Netflix, Amgen, Gartner and Novo Nordisk. Ms. Rossin brings more than 20 years of strategic communications experience to Kyverna, having most recently served as the Head of Public Affairs at Kite, where she was responsible for leading corporate, product and employee communications in addition to patient advocacy. Prior to this role, she served as Vice President, Global Head of Communications at Innate Pharma, an oncology-focused biotech company, where she led both corporate and financial communications. Ms. Rossin also spent more than 12 years at AstraZeneca/MedImmune, where she held multiple U.S. and global communications roles for key therapeutic areas across AstraZeneca's portfolio before serving as the Head of Corporate Affairs at MedImmune, the global biologics research and development arm of AstraZeneca. Before joining AstraZeneca, she held various positions at global public relations agencies working with corporate and healthcare related clients. Inducement Grant In connection with the appointment of Mr. Maziasz as Kyverna's Chief Business Officer, on December 9, 2024 , Kyverna granted Mr. Maziasz an option to purchase 350,000 shares of its common stock (Option). The Option was granted pursuant to the Kyverna Therapeutics, Inc. 2024 Inducement Equity Incentive Plan, as approved by the Compensation Committee of Kyverna's Board of Directors on September 14, 2024 , and was granted as an inducement material to Mr. Maziasz's employment with Kyverna in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price of the Option was $4.86 , the closing price of Kyverna's common stock on December 9, 2024 , the date of grant. The Option will vest over four years, with 25% of the total number of shares subject to the Option vesting on the one-year anniversary of Mr. Maziasz's appointment and 1/48th of the total number of shares subject to the Option vesting monthly thereafter, subject in each case to Mr. Maziasz's continued service to Kyverna on each vesting date. Kyverna is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4). About Kyverna Therapeutics Kyverna Therapeutics, Inc. (Nasdaq: KYTX ) is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead CAR T-cell therapy candidate, KYV-101 is advancing through clinical development with sponsored clinical trials across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center Phase 1/2 trials in the United States and Germany for patients with lupus nephritis. Kyverna's pipeline includes next-generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases. For more information, please visit https://kyvernatx.com . Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." The words, without limitation, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include, without limitation, those related to: the potential impact of the clinical outcomes from the ongoing clinical programs; the potential impact of the new data on the treatment efficacy and safety profile of KYV-101; the potential that the results of the ongoing trials could drastically change the treatment landscape for the targeted autoimmune diseases; Kyverna's goals to develop certain paradigm-shifting treatment options; the potential for KYV-101 to provide durable, immunosuppressant-free remission for autoimmune disease patients; Kyverna's beliefs about the differentiated properties of KYV-101; and Kyverna's clinical trials, investigator-initiated trials and named-patient activities. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to market conditions, and other factors discussed in the "Risk Factors" section of Kyverna's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that Kyverna has filed or may subsequently file with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Kyverna's management team and speak only as of the date hereof, and Kyverna specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Contact: Investors: [email protected] Media: [email protected] SOURCE Kyverna TherapeuticsWhy Miami’s Pop-Tarts Bowl appearance is important even after missing College Football Playoff
Google vs. the feds, Elon Musk vs. Big Tech, and an AI arrest: Tech news roundupCarlsbad, CA, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, today announced the closing of its previously announced underwritten public offering for gross proceeds of approximately $5 million prior to deducting underwriting commissions and offering expenses. The offering is comprised of (i) 158,000 Class A Units with each unit consisting of (a) one share of common stock and (b) one common warrant to purchase one share of common stock (the “Common Warrants”), and (ii) 3,120,688 Class B Units with each unit consisting of (a) one prefunded common stock purchase warrant to purchase one share of common stock (“Prefunded Warrants”) and (b) one Common Warrant. The price per Class A Unit is $1.525 and the price per Class B Unit is $1.5249 (collectively, the “Offering”). The Common Warrants have an exercise price of $1.40 per share, are exercisable at issuance, and have a term expiring five years from issuance. Ladenburg Thalmann & Co. Inc. acted as sole bookrunning manager in connection with this Offering. In addition, the Company has granted the underwriter a 45-day option to purchase up to 491,803 additional shares of common stock and/or Common Warrants, solely to cover over-allotments, if any, at the public offering price less the underwriting discounts and commissions. In connection with the Offering, the Company has elected to reprice approximately one million previously issued warrants to $1.40 per share. The gross proceeds from the Offering to the Company, before deducting underwriting discounts and commissions and other Offering expenses and excluding any proceeds that may be received upon the exercise of the Common Warrants and the exercise of the underwriter’s option to purchase additional shares of common stock and/or Common Warrants, were approximately $5 million. The Company currently intends to use the net proceeds of the Offering primarily to fund our Phase 1 clinical trial of PALI-2108, pre-clinical studies, research and development, and working capital. The securities were offered pursuant to a registration statement on Form S-1 (File No. 333-282883), which was declared effective by the United States Securities and Exchange Commission (“SEC”) on December 12, 2024. The securities may be offered only by means of a prospectus which forms part of the effective registration statement. A preliminary prospectus describing the terms of the Offering has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov . A final prospectus relating to this Offering was filed by the Company with the SEC. Electronic copies of the final prospectus relating to the Offering, when available, may also be obtained by contacting Ladenburg Thalmann & Co. Inc., Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, New York 10019 or by email at prospectus@ladenburg.com . This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. About Palisade Bio Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com . Forward Looking Statements This communication contains “forward-looking” statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the over-allotment option. These forward-looking statements are based on the Company’s current expectations. Forward-looking statements involve risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the intended use of net proceeds from the Offering, the extent of our cash runway; our ability to successfully develop our licensed technologies; the timing and outcome of our current and anticipated applications and studies related to our product candidates; estimates about the size and growth potential of the markets for our product candidates, and our ability to serve those markets, including any potential revenue generated; future regulatory, judicial, and legislative changes or developments in the United States (U.S.) and foreign countries and the impact of these changes; our ability to maintain the Nasdaq listing of our securities; our ability to build a commercial infrastructure in the U.S. and other markets; our ability to compete effectively in a competitive industry; our ability to identify and qualify manufacturers to provide API and manufacture drug product; our ability to enter into commercial supply agreements; the success of competing technologies that are or may become available; our ability to attract and retain key scientific or management personnel; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; our ability to obtain funding for our operations; our ability to attract collaborators and strategic partnerships; and the impact of any global event on our business, and operations, and supply. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon the Company’s current expectations. Forward-looking statements involve risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the Company’s ability to advance its nonclinical and clinical programs, the uncertain and time-consuming regulatory approval process; and the Company’s ability to secure additional financing to fund future operations and development of its product candidates. Additional risks and uncertainties can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2024, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter, including the Registration Statement on Form S-1. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. Investor Relations Contact JTC Team, LLC Jenene Thomas 908-824-0775 PALI@jtcir.com
SANTA CLARA, Calif. , Dec. 13, 2024 /PRNewswire/ -- Marvell Technology, Inc. (NASDAQ: MRVL), today announced a quarterly dividend of $0.06 per share of common stock payable on January 30, 2025 to shareholders of record as of January 10, 2025 . About Marvell To deliver the data infrastructure technology that connects the world, we're building solutions on the most powerful foundation: our partnerships with our customers. Trusted by the world's leading technology companies for over 25 years, we move, store, process and secure the world's data with semiconductor solutions designed for our customers' current needs and future ambitions. Through a process of deep collaboration and transparency, we're ultimately changing the way tomorrow's enterprise, cloud, automotive, and carrier architectures transform—for the better. Marvell® and the Marvell logo are registered trademarks of Marvell and/or its affiliates. For further information, contact: Ashish Saran Senior Vice President, Investor Relations 408-222-0777 ir@marvell.com View original content to download multimedia: https://www.prnewswire.com/news-releases/marvell-technology-inc-declares-quarterly-dividend-payment-302331636.html SOURCE Marvell
Football is different — although this type of stretch is becoming more common in the NFL. “I just kind of put myself in a basketball perspective. Those guys play back to back, so I guess there’s a little merit behind us quote-unquote complaining about it, but they are playing 82 games," Baltimore Ravens safety Kyle Hamilton said. “MLB players are playing 162 games, and we have 17, and we’re trying to fight them to go to 18 right now. I think it’s good in a sense that we’ll see who is most prepared down the stretch, and it’s really challenging for teams — everybody that’s involved.” The Ravens are one of the five teams that are about to go through a three-game, 11-day stretch. The Ravens, Chiefs, Steelers and Texans are playing Sunday, the following Saturday and then the Wednesday after that on Christmas. Chicago has a game this coming Monday night, then plays the following Sunday before a Thursday game on Dec. 26. Before this season, 21 teams in the Super Bowl era had played three games in 11 days, according to Sportradar. In 2024 there are nine stretches like that on the schedule. In addition to the five teams above, four others have already gone through a three-game, 11-day period. The Jets, Seahawks, Saints and Cowboys all had Monday-Sunday-Thursday runs like the Bears are about to face. The Jets and Cowboys managed to go 2-1 during those stretches, but the Seahawks and Saints went 0-3. “Try to win the first one, rest, try to get your body back how it should be,” Baltimore quarterback Lamar Jackson said. “If it’s not 100 percent, try to get it close as possible — just get ready to play football. That’s all.” For Baltimore, the easiest game of the three is in theory the first. As of Thursday afternoon, the Ravens were favored by 16 points at the New York Giants this weekend, according to BetMGM Sportsbook — but Baltimore has already lost to last-place teams like the Raiders and Browns this season. So the Ravens need to be careful not to overlook the lowly Giants. After the trip to New Jersey, Baltimore returns home to face Pittsburgh in a game that figures to be vital to the Ravens' AFC North title hopes. Then there's a road game against AFC South-leading Houston on Christmas. “The big picture is, ‘All hands on deck.’ We’re focused toward playing our best game so far on Sunday,” coach John Harbaugh said. “We’re going to need to do that, and that’s what we’re training and preparing to do. We have a plan for the three-game stretch, and that plan starts with Sunday.” The Ravens played on Christmas last year too, but that was on a Monday, so it wasn't that big a change in the schedule. If there's one factor in Baltimore's favor this season, it's that the Ravens had their open date last week — immediately before their rugged three-game stretch. But that meant Baltimore was among the last teams to have a week off. And the Ravens started earlier than almost anyone else, having been part of the NFL's opening game against Kansas City. “We reported to camp earlier than everybody else for that Thursday night game, and I think KC had their bye a little while ago,” Hamilton said. “I guess we had the longest stretch, continuous, of anybody else. It’s just going to be that much better at the end of it all, when we do what we need to do, and we can look back on that and say, ‘We did that, and we came out and won these three games.’” AP NFL: https://apnews.com/hub/nflStock market today: Wall Street ends mixed after a bumpy weekWagner 81, Springfield 46
Prime Minister and Chairman of Caricom, the Honourable Dickon Mitchell, is poised to deliver the keynote address at the 2024 Connected Caribbean Summit. This year’s event is set to take place between 9–12 December in Miami under the theme “Collaborating for Caribbean Solutions.” Prime Minister Mitchell will address the gathering on Tuesday, 10 December, on the topic “Action Time — Accelerating Caribbean Integration and Development.” The Connected Caribbean Summit (CCS) 2024 is an action-orientated forum organised by the Caribbean Chamber of Commerce (CARICHAM) and designed to facilitate knowledge sharing, networking, enhancing leadership awareness, and driving action and implementation for regional development. This year’s theme focuses on the responsible use of technology for sustainable development, economic and climate resilience, digital transformation, cybersecurity, and artificial intelligence. The summit also seeks to foster greater collaboration among leaders from governments, the private sector, and civil society, addressing key areas and bringing tangible progress for a more sustainable Caribbean. The Hon. Andy Williams, Minister for Mobilisation, Implementation, and Transformation, will act as Prime Minister in the absence of Prime Minister Hon. Dickon Mitchell, who is scheduled to return to the state on Wednesday, 11 December 2024. For more information on the Connected Caribbean Summit go to https://connectedcaribbean.org/ Office of the Prime MinisterCampaigners against wind farm in rural Limerick lobby Dail hopefuls
Researchers from a local university are conducting a community-led research project to map the drug crisis in Surrey. Michael Ma, PhD and Tara Lyons, PhD from Kwantlen Polytechnic University (KPU) are working with the Surrey Union of Drug Users (SUDU) to highlight "the lack of specific research on Surrey’s toxic drug supply crisis, harm reduction and the regulation of people who use drugs," notes a KPU news release Tuesday (Dec. 10). Surrey had the second-highest number of drug overdose deaths in the province for the first nine months of 2024, according to the . Gina Egilson, a board member at SUDU, said, "Surrey's losing more and more people to toxic drug overdoses, with at least four to five people dying every week." “There's a deep urgency to improve the system through more support and resources in Surrey. This research will be an empowering skill-building opportunity that will help guide SUDU's advocacy." In an , Ma noted that the majority of research on overdoses in B.C. is focused on Vancouver's Downtown Eastside, even though most overdoses have occurred in Vancouver, Surrey and Victoria. “For too many years there hasn't been enough focus on the escalating drug crisis in Surrey,” Ma said. “So we want to try to build more capacity and support in Surrey through resources, funding and infrastructure.” The project will draw from people with lived experience of substance use, who will take an "active role as participants and collaborators in the research," notes the KPU release. “This research is just not for pure scholarly academic reasons. It’s a community development project that has a research component. It can be leveraged for social action to generate new social, economic and political policy that could benefit people who are suffering, being misunderstood or being under-researched,” Ma said. Pete Woodrow, a board member at SUDU, said, “I've never seen this kind of collaboration between people of lived experience and established researchers." “It not only creates a bridge of understanding between two groups that would not normally have contact, it also gives us an opportunity to gain a greater handle on where services are most needed. So often the intent of help falls short or misses the mark due to the lack of a proper map of marginalized population.” Lyons added, “We don’t see people as objects of study in the work we're doing. They're experts who are guiding the kind of questions we're going to ask and how we will communicate the information.” A $339,159 grant from the will help fund this project.
Sri Lanka should be vigilant about Adani power deal following US indictment, say expertsAncient Roman home — and luxurious decorations — uncovered in France. See elite finds
According to the study, thermal power plants in Bengal produce 313 kilotonnes of sulphur dioxide annually KOLKATA: Coal-fired thermal power plants in Bengal annually emit 18 times more sulphur dioxide than that generated by stubble-burning in Punjab and Haryana, revealed a report by the Centre for Research on Energy and Clean Air. The findings underscore the need to curb the emissions, with experts advocating the installation of Flue Gas Desulfurization (FGD) system. According to the study, thermal power plants in Bengal produce 313 kilotonnes of sulphur dioxide annually, while 17.8 kilotonnes are generated from burning 8.9 million tonnes of paddy straw in Punjab and Haryana. Assembly Election Results 'Ek hain, toh safe hain' is new 'Maha' mantra of India, says PM Modi in victory speech 'Let us take a pledge to build Golden Jharkhand': Hemant Soren after victory 'Cannot believe Maharashtra results': Uddhav vows to keep fighting But despite the continuous pollution , none of the 14 coal-based plants in Bengal, totalling 13.745 GW of installed capacity, has so far installed an FGD, pushing India to be one of the top sulphur dioxide-emission countries globally. India accounted for over 20% of human-made SO2 emission, showed the study. In 2023, India produced 6,807 kilotonnes of SO2 while generating power, surpassing nations, like Turkey and Indonesia. SO2 transforms into sulfate particles, a major component of PM2.5 pollution that poses severe health risks, including respiratory and cardiovascular diseases. CREA's research shows 96% of particulate pollution from coal plants is secondary, arising from chemical transformations of emitted gases, such as sulphur dioxide. Maharashtra Jharkhand Maharashtra Alliance View i Party View Seats: 288 L + W Majority: 145 BJP+ 229 MVA 47 OTH 12 Leads + Wins : 288 / 288 BJP+ WON Jharkhand Alliance View i Party View Seats: 81 Results Majority: 41 INDIA 56 NDA 24 OTH 1 Results : 81 / 81 INDIA WON Source: PValue Despite the ministry of environment , forests and climate change introducing emission standards in 2015, FGD adoption had been slow, said experts. Till Aug this year, only 39 units across the country installed the system, while work was underway at 238 units. Unlike farmers, who were penalised for stubble-burning, thermal power plants often got leniency and extensions for compliance, said experts. If the FGD system was installed at the units, SO2 emissions from Bengal's coal plants could drop by 64%, from 313 kilotonnes to 113 kilotonnes a year. IIT-Delhi estimates that FGD can reduce the concentration of SO2 by 55% within an 80-km radius and sulfate aerosols by 30% up to 100 km. Experts pointed out installing FGDs involved significant costs -Rs 1 crore to Rs 2 crore per megawatt, adding Rs 0.5-0.6 per unit to electricity generation. But, they said, public health benefits outweighed the installation expenses as better air quality could drastically cut down on hospitalisations and deaths from air pollution. With the installation of an FGD system, Farakka STPS, which emits 46 kilotonnes of sulphur dioxide annually, could see a reduction of 73% and Haldia plant 82%. Mejia TPS, Bakreswar TPS and Budge Budge TPS are also projected to achieve significant cuts. The CREA report highlights the need for policy enforcement and investment in emission-reduction technologies like, FGD system.TikTok is inching closer to a potential ban in the US. So what's next?
Stock Music Market to Grow by USD 650.4 Million from 2023-2028, Report on AI Redefining Market Landscape - Technavio
Stock indexes closed mixed on Wall Street at the end of a rare bumpy week. The S&P 500 ended little changed Friday. The benchmark index reached its latest in a string of records a week ago. It lost ground for the week following three weeks of gains. The Dow Jones Industrial Average slipped 0.2%. The Nasdaq composite edged up 0.1%. Broadcom surged after the semiconductor company beat Wall Street’s profit targets and gave a glowing forecast, highlighting its artificial intelligence products. RH, formerly known as Restoration Hardware, surged after raising its revenue forecast. Treasury yields rose in the bond market. THIS IS A BREAKING NEWS UPDATE. AP’s earlier story follows below. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.Dell, Autodesk, And CrowdStrike Headline Earnings Reports In Holiday-Shortened WeekIndia and Japan on Friday deliberated on a reciprocal provision of supply and services agreement for greater interoperability between the militaries of the two strategic partners amid common concerns of over China's military muscle-flexing in strategic waters. The proposed pact was discussed at a meeting between Defence Minister Rajnath Singh and his Japanese counterpart Gen Nakatani that took place on the sidelines of a regional security conclave in Vientiane, the capital city of Laos. The defence ministry said both sides agreed to enhance cooperation in co-production and co-development of military hardware. "To further improve interoperability between the Indian and Japanese forces, reciprocal provision of supply and services agreement between the two countries and participation of militaries in various bilateral and multilateral exercises were discussed by both the ministers," it said in a statement. The reciprocal supply and services pact, if sealed, would provide for the militaries of the two countries to use each other's bases for repair and replenishment of supplies, besides facilitating scaling up of overall defence cooperation. Rajnath Singh and Gen Nakatani also agreed to explore new areas of cooperation in the air domain, the ministry said. It said the two sides reiterated the importance of India-Japan defence industry and technology cooperation. "Recalling the milestone event of signing of Memorandum of Implementation (MoI) of UNICORN mast in Japan last week, both sides agreed for enhanced cooperation in co-production and co-development in the defence manufacturing sector," it said. The MoI was inked for the co-development of UNICORN (Unified Complex Radio Antenna) mast, a key equipment for warships to increase their stealth characteristics. Rajnath Singh also held a separate bilateral meeting with Philippines Defence Minister Gilberto Teodoro. "Both sides agreed to expand and deepen cooperation in exchange of subject matter experts, defence industry, counter-terrorism, space and maritime domain," the ministry said. Prior to his departure to Delhi, Singh visited the Wat Sisakat temple (a Buddhist temple) in Vientiane, and sought blessings from Mahaveth Chittakaro, Abbot of Sisaket temple. Rajnath Singh arrived in Vientiane on Wednesday, primarily to attend a meeting of the ASEAN Defence Ministers' Meeting Plus (ADMM-Plus). The ADMM-Plus is a platform comprising 10-nation ASEAN (Association of Southeast Asian Nations) and its eight dialogue partners -- India, China, Australia, Japan, New Zealand, Republic of Korea, Russia and the United States. Laos hosted the meeting in its capacity as the current chair of ADMM-Plus. (Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.) Track Latest News Live on NDTV.com and get news updates from India and around the worldHeavy rain helps improve drought conditions in New Hampshire
MINNEAPOLIS — When the Chicago Bears were busy keeping Justin Jefferson quiet last month, the Minnesota Vikings put Jordan Addison to work. With the way Sam Darnold has been throwing the ball, the difficult task of defending this passing attack has become quite the chore. The Bears will be retesting on Monday night in Minnesota. “We always say that we’re the best duo in the entire league,” Jefferson said after he and his sidekick reached a new height in the rich history of Vikings receivers last week in a 42-21 victory over Atlanta that served as a breakthrough of sorts for an offense that hadn't yet hit its highest gear. Jefferson and Addison in that game became the first pair of players in the franchise's 64 seasons to each record at least 100 yards receiving and two touchdown catches. Addison scored three times, giving him 17 touchdowns in just 28 career games. Only Randy Moss (28), Rob Gronkowski (27), Ja'Marr Chase (22), Odell Beckham Jr. (19) and Larry Fitzgerald Jr. (18) scored more before turning 23. Addison, the team's first-round draft pick last year, has had a rocky start to his career off the field with a couple of driving incidents that could still lead to punishment from the NFL . After a contrite arrival at training camp and a slow start to this season as he worked through a severe ankle sprain to make the opener and then suffered another one on the opposite foot, Addison has caught stride along with Darnold as the revitalized quarterback keeps delivering game-winning performances for the Vikings (11-2). Addison has 23 catches for 410 yards and five scores over the last four games, helping the Vikings stretch their winning streak to six despite a constant effort by opponents to send safeties toward Jefferson for double or sometimes triple coverage. “Especially with how Justin gets defended, normally the player that’s defending Jordan or even if it’s within zone coverages, these guys know that they’re being told this guy will be wide open if you don’t get your hands on him, and that couldn’t be more true," Vikings coach Kevin O'Connell said. “Now, he’s actually proven that he can play through that contact and play down the field through contact.” Addison's catch early in the third quarter at Chicago on Nov. 24 was a prime example of that ability to maintain balance and control despite his smaller stature at 5-foot-11 and 175 pounds. Darnold dropped a perfectly placed ball into the space in the zone coverage between linebacker T.J. Edwards and safety Jonathan Owens, whose shoulder-first attempt to knock Addison down near the sideline failed badly during a 69-yard catch and run . “That’s all part of what we projected with Jordan, knowing he had elite quickness, separation skills, fantastic hands and ball tracking,” O'Connell said. “As he’s gotten stronger, he’s put a lot of work in. It’s showing up with his play style.” Jefferson, who is five years into a spectacular career of rewriting the NFL receiving record books, had just two receptions for 27 yards in that 30-27 overtime win over the Bears in Week 12. But Addison had eight catches for 162 yards, tight end T.J. Hockenson had seven receptions for 114 yards and Aaron Jones rushed for a season-high 106 yards that afternoon. “We assume that they’re going to come out and try to stop Justin, but we could get there and it could be something completely different, so everybody just has to be ready to roll at all times,” Jones said. “I feel like we have one of the best skill groups in the league now.” Darnold was serenaded with some “MVP” chants late in the game last week as the Vikings pulled away with three fourth-quarter touchdowns. He has completed 68% of his passes over the last four games for 1,158 yards and 11 touchdowns without an interception. “I think the biggest thing for me is just continuing to make good decisions and being able to, when I do let the ball rip, let it rip with confidence,” Darnold said. Bears tight end Cole Kmet acknowledged the mental toll this season has taken on him, with the team on a seven-game losing streak. A recent pep talk from his father, Frank, who starred as a defensive lineman at Purdue, helped him find perspective. “He was saying he’d give anything to go back and just to play one more game, to be in the shape that I’m in right now and to go out and play football. I think that’s kind of the perspective that I want to have going forward," Kmet said. “It’s a hard deal, for sure. I just have to keep the type of mindset that this type of adversity will only make me stronger going forward.” The first game with defensive coordinator Eric Washington calling the plays instead of coach Matt Eberflus, who was fired on Nov. 29 , didn't go well. The Bears gave up a season-most 38 points and matched their second-worst total by allowing 452 yards in a loss to San Francisco. Interim coach Thomas Brown said communication issues contributed to breakdowns in coverage. “I wouldn’t say it’s anything with a new play caller because we still have the same defense. We’ve all been with each other since the spring. The plays are the same. It’s just different flows,” Owens said. "It just comes down to us communicating and us executing it. After playing last week in all purple, the Vikings will don their “ Winter Warrior ” look with not only white jerseys and pants but the first usage of a white helmet in franchise history. “The helmet’s already insane,” outside linebacker Jonathan Greenard said. “I feel like I might go to sleep in it. I’m excited to put it on.”
